A novel antibody-drug conjugate can drastically reduce the risk of progression in HER2-low breast cancer, new Phase 3 data presented at the European Society of Molecular Oncology (ESMO) Congress has ...

Daraxonrasib received a standing ovation at the ASCO 2026 Annual Meeting, Breakthrough Therapy and Orphan Drug designations from the FDA, and global attention for effectively doubling survival in ...

A frontline chemotherapy-free strategy using a tyrosine kinase inhibitor and immunotherapy beats the conventional chemotherapy approach for treating Philadelphia-positive acute lymphoblastic leukaemia ...

Brentuximab vedotin (Adcetris, Takeda) is now on the PBS as part of the multi-drug BrECADD chemotherapy regimen for front-line treatment in adult patients with advanced stage CD30+ Hodgkin lymphoma.

Acute ischaemic stroke patients with large-vessel occlusion in the anterior circulation presenting in the days after symptom onset can still clinically benefit from endovascular therapy, as can those ...

The Royal College of Pathologists of Australasia has applied for Medicare funding of kappa free-light chain (kFLC) index testing for diagnosing multiple sclerosis. The test was included in the revised ...

A Victorian coroner has called on the TGA to consider a ban on prescribing unapproved peptides after a 75-year-old man died from complications of a cardiac arrest after injecting the experimental ...

There’s not enough good quality evidence to show medical cannabis delivers benefits for the treatment of insomnia, a panel of global researchers have found. The recently published Cochrane review ...

The Medical Services Advisory Committee has endorsed extending Medicare and PBS supervision criteria for extracorporeal photopheresis, opening the door for dermatologists to supervise the treatments.

JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

Under bright lights in auditoriums around the world, live injecting demonstrations have become a centrepiece of cosmetic dermatology conferences, but clinicians are worried they come at an ethical ...

Trials of agents for the management of IgA nephropathy dominated the American Society of Nephrology’s 2026 Kidney Week, including three featured as high-impact trials in the opening plenary and four ...